Today: 29 June 2026
CoreWeave stock rebounds in regular trading as data-center funding worries shadow earnings week
23 February 2026
1 min read

CoreWeave stock rebounds in regular trading as data-center funding worries shadow earnings week

New York, Feb 23, 2026, 11:38 EST — Regular session

  • CoreWeave climbed roughly 2.4% on Monday, trimming some of last week’s losses.
  • Questions over how the Pennsylvania data-center project linked to Blue Owl will get financed kept traders’ attention.
  • Quarterly results are scheduled for release on Feb. 26, the company said.

CoreWeave clawed back 2.4% to $91.40 late this morning, rebounding after a sharp selloff late last week that had stirred up fresh concerns about how the AI cloud company is financing its expansion.

This is a big deal for CoreWeave. The company burns a lot of cash on things like servers, chips, power deals, and new locations. The stock price has basically been a proxy for Wall Street’s bet on whether AI infrastructure will keep getting financed.

Worries ramped up after a report surfaced about Blue Owl Capital having trouble securing debt financing for a $4 billion data center in Pennsylvania—CoreWeave is slated as the tenant. Lenders, according to the report, were wary of upping their exposure to AI companies carrying sub-investment-grade ratings. S&P Global Ratings has CoreWeave’s debt at B+.

CoreWeave ended Friday at $89.25 a share, dropping from its previous close of $97.14, then found some footing on Monday.

Focus shifts to the company’s fourth-quarter numbers, with investors zeroing in on demand, but especially how fast spending is happening—and what it’s costing to bankroll that growth. CEO Michael Intrator, in the previous quarterly update, insisted that CoreWeave’s role as “the essential cloud for AI” had “never been stronger.” Benzinga

CoreWeave will post its results Thursday, Feb. 26, and plans a conference call at 5:00 p.m. Eastern, according to a statement from the company earlier this month.

CoreWeave made its Nasdaq debut in March 2025, launching its IPO at $40 a share and trading under the ticker CRWV, the company said in a statement.

In late January, Nvidia said it would pump $2 billion into CoreWeave, buying in at $87.20 a share. Both firms pointed to data-center growth and infrastructure as the focus for the funds.

Bulls face a clear risk here. Should lenders push for better yields, or if major projects get delayed, CoreWeave might end up with pricier debt, stricter loan conditions, or a drag on capacity growth. Any of these can dent a stock that’s been valued for speed.

Traders this week have their eyes on the Feb. 26 results, looking for new details on funding, data-center schedules, and any signs of shifting customer demand. Management’s comments around capital needs through 2026 are also on the radar.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • MetLife (MET) Options Play Targets Upside After Q1 Premiums Jump
    June 29, 2026, 1:11 PM EDT. MetLife (MET) posted a 10% jump in Q1 premiums, with big gains out of Asia (22%), Latin America (20%), and US Group Benefits (15%). The company is pushing AI-driven efficiency to widen margins, and is looking for close to 25% EPS growth by FY2028 as buybacks and investment income help. One options play here is a September 77.5/87.5/92.5 call spread risk reversal, which lets investors keep upside potential but contain downside risk. The strategy mixes long calls, short puts, and short higher strikes to cut net cost and keep a cap on volatility going into August 6 earnings. A 17.2% return on equity points to healthy fundamentals. The setup leans on MET's trend, with risk defined if the market shifts.
Johnson & Johnson stock falls on DePuy sale talk — what to watch next for JNJ shares
Previous Story

Johnson & Johnson stock falls on DePuy sale talk — what to watch next for JNJ shares

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Next Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Go toTop